Clinical Trials Browser

Active not recruiting × OTHER × Gemtuzumab × Clear all

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05716009 2025-05-06

GO-TAG

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05599360 2024-12-02

Vyxeos for Induction of Low- or Intermediate-risk.

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression